ATE293883T1 - Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen - Google Patents
Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungenInfo
- Publication number
- ATE293883T1 ATE293883T1 AT97901425T AT97901425T ATE293883T1 AT E293883 T1 ATE293883 T1 AT E293883T1 AT 97901425 T AT97901425 T AT 97901425T AT 97901425 T AT97901425 T AT 97901425T AT E293883 T1 ATE293883 T1 AT E293883T1
- Authority
- AT
- Austria
- Prior art keywords
- antioxidants
- liver disease
- cholestatic liver
- treat cholestatic
- treat
- Prior art date
Links
- 206010008635 Cholestasis Diseases 0.000 title abstract 2
- 239000003963 antioxidant agent Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010067125 Liver injury Diseases 0.000 abstract 1
- 231100000359 cholestasis Toxicity 0.000 abstract 1
- 230000007870 cholestasis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 231100000753 hepatic injury Toxicity 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1004996P | 1996-01-16 | 1996-01-16 | |
| PCT/US1997/000403 WO1997025864A1 (en) | 1996-01-16 | 1997-01-15 | Use of antioxidant agents to treat cholestatic liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE293883T1 true ATE293883T1 (de) | 2005-05-15 |
Family
ID=21743557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97901425T ATE293883T1 (de) | 1996-01-16 | 1997-01-15 | Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6069167A (de) |
| EP (1) | EP0893949B1 (de) |
| AT (1) | ATE293883T1 (de) |
| AU (1) | AU724620B2 (de) |
| CA (1) | CA2242991C (de) |
| DE (1) | DE69733132D1 (de) |
| WO (1) | WO1997025864A1 (de) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9722361D0 (en) * | 1997-10-24 | 1997-12-17 | Pharma Nord Uk Ltd | Pharmaceutical formulation for treating liver disorders |
| US6616942B1 (en) * | 1999-03-29 | 2003-09-09 | Soft Gel Technologies, Inc. | Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing |
| US6623734B2 (en) * | 2000-06-22 | 2003-09-23 | Soft Gel Technologies, Inc. | Super absorption coenzyme Q10 |
| US6855733B2 (en) * | 2001-01-24 | 2005-02-15 | Soft Gel Technologies, Inc. | Formulation and manufacturing process for coenzyme Q10 soft gel capsules |
| US6596762B2 (en) | 2001-05-17 | 2003-07-22 | The Regents Of The University Of Colorado | Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis |
| US20080089877A1 (en) * | 2003-08-14 | 2008-04-17 | Udell Ronald G | Super Absorption Coenzyme Q10 |
| US20070026090A1 (en) * | 2003-09-05 | 2007-02-01 | Oren Tirosh | Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium |
| US8105583B2 (en) * | 2003-09-29 | 2012-01-31 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 |
| US8124072B2 (en) | 2003-09-29 | 2012-02-28 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 |
| US7169385B2 (en) * | 2003-09-29 | 2007-01-30 | Ronald G. Udell | Solubilized CoQ-10 and carnitine |
| US20050107465A1 (en) * | 2003-10-01 | 2005-05-19 | Papas Andreas M. | Composition for treating inflammatory bowel disease |
| US20050074444A1 (en) * | 2003-10-01 | 2005-04-07 | Papas Andreas M. | Coenzyme Q10 treatment for cystic fibrosis |
| TW200524579A (en) * | 2003-11-28 | 2005-08-01 | Kaneka Corp | Composition for protecting liver functions |
| US7790190B2 (en) * | 2004-03-20 | 2010-09-07 | Yasoo Health, Inc. | Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
| US7284385B2 (en) * | 2004-09-16 | 2007-10-23 | Hess Spencer W | Pre-dried air reactivation for diesel fuel heated dessicant reactivator |
| DE102004049339A1 (de) | 2004-10-08 | 2006-04-13 | Basf Ag | Verfahren zur Reinigung von phosphorhaltigen Chelat-Liganden |
| CA2598792A1 (en) * | 2005-03-02 | 2006-09-08 | Metanomics Gmbh | Process for the production of fine chemicals |
| US20070167422A1 (en) * | 2006-01-18 | 2007-07-19 | Yu Kwok S | Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin |
| CN101594878A (zh) | 2006-09-18 | 2009-12-02 | 雷普特药品公司 | 通过给予受体相关蛋白（rap）-缀合物对肝病症的治疗 |
| US8343541B2 (en) | 2007-03-15 | 2013-01-01 | Soft Gel Technologies, Inc. | Ubiquinol and alpha lipoic acid compositions |
| KR20100015786A (ko) * | 2007-03-21 | 2010-02-12 | 랩터 파마슈티컬 인코포레이티드 | 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드 |
| EP2346519B1 (de) | 2008-10-02 | 2015-12-02 | George Zabrecky | Verfahren und formulierungen zur behandlung von chronischer lebererkrankung |
| PL3400944T3 (pl) | 2010-11-04 | 2020-11-16 | Albireo Ab | Inhibitory ibat w leczeniu chorób wątroby |
| PT2637646T (pt) * | 2010-11-08 | 2016-08-17 | Albireo Ab | Uma combinação farmacêutica que compreende um inibidor do ibat e um sequestrador de ácido biliar |
| SG10201909122QA (en) * | 2011-10-28 | 2019-11-28 | Lumena Pharmaceuticals Inc | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
| US20140323412A1 (en) | 2011-10-28 | 2014-10-30 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| KR102560954B1 (ko) | 2014-06-25 | 2023-07-31 | 이에이 파마 가부시키가이샤 | 고형 제제 및 그의 착색 방지 또는 착색 감소 방법 |
| EP3012252A1 (de) | 2014-10-24 | 2016-04-27 | Ferring BV | Kristalline Form von elobixibat |
| US20160367620A1 (en) | 2015-06-19 | 2016-12-22 | Harry B. Demopoulos | Glutathione |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| CN111032019B (zh) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | 考来烯胺颗粒、口服考来烯胺制剂及其用途 |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP3802504B1 (de) | 2018-06-05 | 2023-01-18 | Albireo AB | Benzothia(di)azepinverbindungen und ihre verwendung als gallensäuremodulatoren |
| EP3810084A1 (de) | 2018-06-20 | 2021-04-28 | Albireo AB | Pharmazeutische formulierung von odevixibat |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| DK3921028T3 (da) | 2019-02-06 | 2023-01-23 | Albireo Ab | Benzothiadiazepinforbindelser og anvendelse deraf som galdesyremodulatorer |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| DK4069360T3 (da) | 2019-12-04 | 2024-02-26 | Albireo Ab | Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer |
| JP7696897B2 (ja) | 2019-12-04 | 2025-06-23 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| ES2972045T3 (es) | 2019-12-04 | 2024-06-10 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| CN114761018B (zh) | 2019-12-04 | 2025-12-02 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| CN116157389B (zh) | 2020-08-03 | 2026-02-10 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| JP2023549226A (ja) | 2020-11-12 | 2023-11-22 | アルビレオ エービー | 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット |
| WO2022117778A1 (en) | 2020-12-04 | 2022-06-09 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0125252A1 (de) * | 1982-11-16 | 1984-11-21 | MOTSCHAN, Georges | Neue verwendung eines einzelnen vitamins oder einer kombination verschiedener vitamine |
| CA2080818A1 (en) * | 1990-05-16 | 1991-11-17 | Zbigniew Walaszek | Formula and method for the prevention and treatment of hypercholesterolemia and cellular hyerproliferative disorders |
| US5308627A (en) * | 1990-08-07 | 1994-05-03 | Umbdenstock Jr Anthony J | Nutritional supplement for optimizing cellular health |
| CA2125888C (en) * | 1992-01-06 | 2002-08-27 | Harry B. Demopoulos | Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty |
| CN1080855A (zh) * | 1993-05-22 | 1994-01-19 | 黎均耀 | 维生素矿物质防癌复方 |
| DE4322070A1 (de) * | 1993-07-02 | 1995-01-12 | Ploch Eva Marina | Umweltkapsel |
-
1997
- 1997-01-15 AT AT97901425T patent/ATE293883T1/de not_active IP Right Cessation
- 1997-01-15 CA CA002242991A patent/CA2242991C/en not_active Expired - Lifetime
- 1997-01-15 US US08/784,247 patent/US6069167A/en not_active Expired - Fee Related
- 1997-01-15 DE DE69733132T patent/DE69733132D1/de not_active Expired - Lifetime
- 1997-01-15 EP EP97901425A patent/EP0893949B1/de not_active Expired - Lifetime
- 1997-01-15 AU AU15329/97A patent/AU724620B2/en not_active Expired
- 1997-01-15 WO PCT/US1997/000403 patent/WO1997025864A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP0893949A1 (de) | 1999-02-03 |
| CA2242991C (en) | 2007-07-24 |
| US6069167A (en) | 2000-05-30 |
| AU724620B2 (en) | 2000-09-28 |
| EP0893949B1 (de) | 2005-04-27 |
| DE69733132D1 (de) | 2005-06-02 |
| EP0893949A4 (de) | 2002-01-02 |
| CA2242991A1 (en) | 1997-07-24 |
| WO1997025864A1 (en) | 1997-07-24 |
| AU1532997A (en) | 1997-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE293883T1 (de) | Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen | |
| ATE198044T1 (de) | Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges | |
| ATE207356T1 (de) | Verwendung von tiagabin zur behandlung von schlafstörungen | |
| UA26213C2 (uk) | Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| CY1111912T1 (el) | Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων | |
| DE69523745D1 (de) | Gel zur behandlung von hauterkrankungen und zur desinfizierung von haut | |
| BR9502707A (pt) | Composto composição farmacêutica e método para o tratamento de uma afecção | |
| DK0942740T3 (da) | Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme | |
| DE69805973D1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
| ATE230757T1 (de) | Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten | |
| MD990262A (en) | Method of prophylaxis or delay of the Alzheimer disease start and therapeutic product effective for prevention of said disease | |
| DE69526937D1 (de) | Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen | |
| ATE303817T1 (de) | Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| DE60008143D1 (de) | Lipoxin-a4 und deren analoge zur behandlung von trockenen augen | |
| EP1109548A4 (de) | Zusammensetzungen und verfahren zur behandlung und vorbeugung von knochenkrankheiten unter verwendung von tocotrienole | |
| DE69739970D1 (de) | Methode zur behandlung sexueller fehlfunktionen | |
| DE69725879D1 (de) | VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN | |
| DE69405919D1 (de) | Zusammensetzungen zur Behandlung von Keratinfasern | |
| ATE453402T1 (de) | Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis | |
| DE69825279D1 (de) | Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz | |
| ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| DE60015791D1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
| ATE332688T1 (de) | Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung | |
| ATE234614T1 (de) | Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |